The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens innovation in the digital healthcare sector, Abbott has secured CE Mark approval for the world's first technology combining glucose and ketone monitoring in a single sensor. According to reports, this new biowearable aims to help patients detect rising ketone levels early to prevent diabetic ketoacidosis (DKA). The dual sensor allows users to manage daily glucose levels through the established Libre ecosystem, marking a significant shift in diabetes management.
This milestone comes amid intense competition in the medical device sector, as Abbott seeks to bolster its market share against rivals like Dexcom. Per market data, FreeStyle Libre sales have shown robust growth in recent quarters, with segment revenue exceeding $1.5 billion in Q1 2024 (per company earnings reports). Securing European regulatory approval is a strategic pillar for global expansion prior to a potential U.S. launch.
Sign in to access this content
Sign InABT stock stood at $103.45 (close May 26, 2026) as investors monitor the commercial rollout of the new sensor across Europe. Looking at the economic calendar, traders are eyeing the U.S. Initial Jobless Claims on May 21, which could influence broader market sentiment toward healthcare and growth stocks. Technical support for the stock remains near the $100 level, while analysts view a break above $110 resistance as the next key target.